App-Quantinova.ai

Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).

Amir Goldkorn - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Epidermal growth factor receptor mRNA expression in circulating tumor cells as a potential mechanism of molecular escape from regorafenib therapy.

Satoshi Matsusaka - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Regorafenib

Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.

Marie Lena Johanna Tzschaschel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).

Ugo De Giorgi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Use of a nanotechnology-based system for the prospective characterization of circulating tumor cells in head and neck cancer patients.

Joseph Michael Caster - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

The rational use of detection of CTC and serum HER2 ECD for HER2-positive advanced breast cancer patients. - Publication Only: Breast CancerHER2/ER

Jinmei Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

ERASE: Elimination of recurring artifacts and stochastic errors: An NGS analysis approach and its application to liquid biopsy samples.

Nicholas Kamps-Hughes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating tumor cells as an early detection tool for BRCA positive women?

Georg Pfeiler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Does immune checkpoint inhibitor-induced thyroid dysfunction impact on side effect profile? A restrospective cohort study.

Jack Patrick Gleeson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypothyroidism

N/A

A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naive patients with progressive metastatic castration resistant prostate cancer (mCRPC).

Daniel Costin Danila - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Very-small-nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis (VM) in metastatic castration-resistant prostate cancer (mCRPC).

Jie-Fu Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Benefit from next-generation ADT in AR-V7 positive patients.

Julie Steinestel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.

Edwin M. Posadas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

High sensitivity and specificity NGS analysis of prostate and kidney cancer samples using a novel liquid biopsy workflow.

Cristian Ionescu-Zanetti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Characterization of CTCs isolated from patients with recurrent ovarian cancer using an antibody-free CTC isolation device.

Alpa Manchandia Nick - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Effect of circulating tumor cells (CTCs) on overall survival in metastatic medullary thyroid cancer (metMTC).

Jian Yu Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

N/A

Accurate detection of circulating tumor cells (CTCs) in patients with metastatic papillary thyroid cancer (MPTC) via an interphase fluorescence in situ hybridization (IFISH) assay.

Jian Yu Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Papillary carcinoma

N/A

Evaluation of anti-cancer stem cell activity of the anti-DLL4 antibody MEDI0639 in a phase I clinical trial of SCLC.

Haifeng Bao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

MEDI 0639

Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive lung cancer patients.

Myoung Shin Kim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

A single cell genomic signature to detect homologous recombination deficiency (HRD) and PARP inhibitors sensitivity using patients circulating tumor cells (CTCs).

Gordon Vansant - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Filters

1671 Abstracts